Rockwell Medical Inc (NASDAQ:RMTI)’s traded shares stood at 0.3 million during the last session, with the company’s beta value hitting 1.51. At the close of trading, the stock’s price was $3.64, to imply an increase of 2.25% or $0.08 in intraday trading. The RMTI share’s 52-week high remains $4.57, putting it -25.55% down since that peak but still an impressive 68.13% since price per share fell to its 52-week low of $1.16. The company has a valuation of $112.95M, with an average of 0.64 million shares in intraday trading volume over the past 10 days and average of 473.75K shares over the past 3 months.

Analysts have given a consensus recommendation of Buy for Rockwell Medical Inc (RMTI), translating to a mean rating of 1.00. Of 1 analyst(s) looking at the stock, 0 analyst(s) give RMTI a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 1 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at 0.01.

Rockwell Medical Inc (NASDAQ:RMTI) trade information

After registering a 2.25% upside in the last session, Rockwell Medical Inc (RMTI) has traded red over the past five days. The 5-day price performance for the stock is -0.55%, and 19.74% over 30 days. With these gigs, the year-to-date price performance is 92.59%. Short interest in Rockwell Medical Inc (NASDAQ:RMTI) saw shorts transact 0.4 million shares and set a 0.54 days time to cover.

The extremes give us $9 and $9 for target low and target high price respectively. As such, RMTI has been trading -147.25% off suggested target high and -147.25% from its likely low.

Rockwell Medical Inc (RMTI) estimates and forecasts

Looking at statistics comparing Rockwell Medical Inc share performance against respective industry, we note that the company has outperformed competitors. Rockwell Medical Inc (RMTI) shares are 120.61% up over the last 6 months, with its year-to-date growth rate higher than industry average at 82.35% against 12.30%. Revenue is forecast to grow 114.30% this quarter before jumping 120.00% for the next one. The rating firms project that company’s revenue will grow 19.80% compared to the previous financial year.

Revenue forecast for the current quarter as set by 2 analysts is 26.5M. Meanwhile, for the current quarter, a total of 2 analyst(s) estimate revenue growth to 25.16M.Earnings reports from the last fiscal year show that sales brought in 23.77M and 22.09M respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to rise 11.50% before jumping 13.90% in the following quarter.

An assessment of the company’s 5-year growth patterns shows that annual earnings grew an estimated 44.20% for the past 5-year period. While 2024 is set for a 91.67% return in earnings, projections for the next 5 years are at 38.00% annually.

RMTI Dividends

Rockwell Medical Inc has its next earnings report out on 2024-Nov-12. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.

Rockwell Medical Inc (NASDAQ:RMTI)’s Major holders

Rockwell Medical Inc insiders hold 11.84% of total outstanding shares, with institutional holders owning 20.77% of the shares at 23.56% float percentage. In total, 20.77% institutions holds shares in the company, led by ARMISTICE CAPITAL, LLC. As of 2024-06-30, the company held over 3.22 million shares (or 10.9852% of shares), all amounting to roughly $5.67 million.

The next major institution holding the largest number of shares is VANGUARD GROUP INC with 1.12 million shares, or about 3.8131% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $1.97 million.